MedGenome Launches India's First Genome-Wide Methylation-Based Precision Diagnostic Test for CNS Tumors

Strategic Insights -

MedGenome, a Bangalore-based genomic diagnostics and research services firm, has launched India's first genome-wide methylation-based precision diagnostic test for CNS tumors, called the CNS Tumor Methylation Classifier. This advanced diagnostic tool analyzes DNA methylation patterns to classify central nervous system (CNS) tumors, enabling more precise diagnosis and personalized treatment planning. The test can differentiate over 90 classes of brain and CNS tumors, helping to resolve diagnostic discrepancies and identify novel tumor types.

Key Takeaways:

  • The CNS Tumor Methylation Classifier is India's first genome-wide methylation-based precision diagnostic test for CNS tumors, launched by MedGenome.
  • The test analyzes DNA methylation patterns to classify CNS tumors, enabling more precise diagnosis and personalized treatment planning.
  • The test can differentiate over 90 classes of brain and CNS tumors, including morphologically similar tumours.
  • The classifier complements conventional Histology and increases diagnostic specificity, enabling accurate tumor subtyping for better prognosis.
  • Brain tumors can be either primary (starting in the brain) or metastatic (spreading to the brain from other parts of the body), and not all brain tumors are cancerous.
  • Cancerous brain tumors tend to grow more rapidly than non-cancerous ones.

Statistics:

  • Over 120 different types of brain tumors, lesions, and cysts exist, according to Johns Hopkins Medicine.
  • The CNS Tumor Methylation Classifier can differentiate over 90 classes of brain and CNS tumors.
  • MedGenome's CEO VL Ramprasad stated that "No two cancers are truly the same, even in patients with the same diagnosis."

Sources:

  • Johns Hopkins Medicine
  • Mayo Clinic
  • MedGenome
  • Contify.com
  • IE Online Media Services Pvt. Ltd.